



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



MBP146-78

Item No. 41083

CAS Registry No.: 188343-77-3
Formal Name: 4-[2-(4-fluorophenyl)-5-(1-methyl-4-piperidinyl)-1H-pyrrol-3-yl]-pyridine
MF: $C_{21}H_{22}FN_3$
FW: 335.4
Purity: $\geq 98\%$
Supplied as: A solid
Storage: -20°C
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MBP146-78 is supplied as a solid. A stock solution may be made by dissolving the MBP146-78 in the solvent of choice, which should be purged with an inert gas. MBP146-78 is slightly soluble (0.1-1 mg/ml) in ethanol and DMSO.

Description

MBP146-78 is an inhibitor of parasitic cGMP-dependent protein kinases (PKGs; IC_{50} s = 1.9 and 1 nM for the *E. tenella* and *T. gondii* enzymes, respectively).¹ It inhibits *P. berghei* sporozoite development into liver-stage parasites in HepG2 cells in a concentration-dependent manner.² MBP146-78 (50 mg/kg) prevents *P. yoelii* liver infection in *P. yoelii*-infected mice. It increases survival time in *P. berghei*-infected mice when administered at a dose of 50 mg/kg twice per day for eight days.¹ MBP146-78 (50 mg/kg two times per day) increases survival in *T. gondii*-infected mice and prevents secondary reinfection in the same mice.³

References

1. Diaz, C.A., Allocco, J., Powles, M.A., *et al.* Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): Antiparasitic activity of a PKG inhibitor. *Mol. Biochem. Parasitol.* **146(1)**, 78-88 (2006).
2. Panchal, D. and Bhanot, P. Activity of a trisubstituted pyrrole in inhibiting sporozoite invasion and blocking malaria infection. *Antimicrob. Agents Chemother.* **54(10)**, 4269-4274 (2010).
3. Nare, B., Allocco, J.J., Liberator, P.A., *et al.* Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: Gamma interferon is required for efficacy. *Antimicrob. Agents Chemother.* **46(2)**, 300-307 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/27/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM